Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diphtheria, tetanus and pertussis vaccine infant- Tianjin CanSino Biotechnology

Next Previous
Drug Profile

Diphtheria, tetanus and pertussis vaccine infant- Tianjin CanSino Biotechnology

Alternative Names: Component pertussis-based infants vaccine; Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed - Tianjin CanSino Biotechnology; DTcP vaccine (infant)- Tianjin CanSino Biotechnology

Latest Information Update: 17 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tianjin CanSino Biotechnology
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 23 Mar 2025 CanSino Biologics initiates a phase III trial for Diphtheria, Pertussis and Tetanus (Prevention, In infants) in China (IM, Injection) (NCT06857370)
  • 20 Mar 2025 CanSino Biologics plans a phase III trial for Diphtheria, Pertussis and Tetanus (Prevention, In infants) in March 2025 (NCT06857370)
  • 25 Aug 2023 Phase-III clinical trials in Tetanus (In infants, Prevention) in China (IM) (NCT05951725)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top